Hospira (NYSE: HSP)‘s stock had its “underperform” rating reaffirmed by Zacks in a research note issued on Friday. They currently have a $29.00 price target on the stock.
Zacks‘ analyst wrote, “Hospira’s fourth quarter 2012 adjusted earnings of $0.55 per share were 7.8% below the year-ago figure. Hospira is going through a rough patch due to the ongoing manufacturing challenges at its Rocky Mountain facility as well as issues with the Symbiq/Plum pumps. The ongoing manufacturing issues at its Rocky Mountain facility have hurt the company’s earnings over the last few quarters. The issue, until resolved, will remain a major overhang on the stock. Manufacturing issues at the company’s other facilities, such as at Lake Forest, McPherson, Austin and IKKT are further challenges for Hospira. In view of these concerns we maintain our Underperform recommendation on the stock.”
Other equities research analysts have also recently issued reports about the stock. Analysts at UBS AG upgraded shares of Hospira from a “sell” rating to a “neutral” rating in a research note to investors on Friday, March 8th. They now have a $30.00 price target on the stock, up previously from $28.00. Separately, analysts at RBC Capital cut their price target on shares of Hospira from $26.00 to $25.00 in a research note to investors on Wednesday, March 6th. Finally, analysts at Gabelli downgraded shares of Hospira from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, February 26th.
Hospira (NYSE: HSP) traded up 1.61% on Friday, hitting $32.25. Hospira has a 52-week low of $28.62 and a 52-week high of $38.49. The stock’s 50-day moving average is currently $31.81. The company has a market cap of $5.334 billion and a price-to-earnings ratio of 118.43.
Hospira (NYSE: HSP) last released its earnings data on Wednesday, February 13th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.01. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the company posted $0.51 earnings per share. The company’s quarterly revenue was up 8.4% on a year-over-year basis. Hospira has set its FY13 guidance at $2.05-2.20 EPS. Analysts expect that Hospira will post $2.03 EPS for the current fiscal year.
Hospira, Inc. (Hospira) is a specialty pharmaceutical and medication delivery company. Hospira’s portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.